The p53 gene in breast cancer: Prognostic value of complementary DNA sequencing versus immunohistochemistry

Journal of the National Cancer Institute

Volumn 88, Issue 3-4, 1996, Pages 173-182

  Sjögren, Sigrid ^a   Inganäs, Mats ^b   Norberg, Torbjörn ^b   Lindgren, Anders ^a,c   Nordgren, Hans ^a   Holmberg, Lars ^a   Bergh, Jonas ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^b GE Healthcare Bio Sciences AB   (Sweden)

^c FALUN HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN P53;

ADULT; AGED; ARTICLE; BREAST CANCER; BREAST CARCINOGENESIS; CANCER SURVIVAL; DNA SEQUENCE; HUMAN; HUMAN TISSUE; TUMOR SUPPRESSOR GENE;

ADULT; AGED; BASE SEQUENCE; BREAST NEOPLASMS; DNA PRIMERS; DNA, COMPLEMENTARY; FEMALE; GENES, P53; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; POINT MUTATION; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RNA, NEOPLASM; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030058617     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/88.3-4.173     Document Type: Article

References (39)

1. Lane D, p53. guardian of the genome [see comment citations in Medline]. Nature 1992;358:15-6.
2. Frebourg T, Friend SH. The importance of p53 gene alterations in human cancer: is there more than circumstantial evidence? J Natl Cancer Inst 1993;85:1554-7
3. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hosteller R, Cleary K, et al Mutations in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-8.
4. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor gene. Nature 1991;351:453-6.
5. Harris C, Hollstein M, Rosenberg S. p53 Tumor suppressor gene. PPO updates. In: Principles and practice of oncology 6, No. 10. 1992.
6. Yonish-Rouach E, Resnitzky D, Lofem J, Sachs L, Kimchi A, Oren M. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin -6. Nature 1991;352:345-7.
7. Thor AD, Moore DH II, Edgerton SM, Kawasaki ES, Reihaus E, Lynch HT, et al. Accumulation of p53 tumor suppressor gene protein: an independent marker of prognosis in breast cancers. J Natl Cancer Inst 1992; 84:845-55.
8. Elledge RM, Fuqua SA, Clark GM, Pujol P, Allred DC, McGuire WL. Prognostic significance of p53 gene alterations in node-negative breast cancer. Breast Cancer Res Treat 1993;26:225-35.
9. Thorlacius S, Børresen AL. Eyfjörd JE. Somatic p53 mutations in human breast carcinomas in an Icelandic population: a prognostic factor. Cancer Res 1993;53:1637-41.
10. Bartek J, Iggo R, Gannon J, Lane DP. Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene 1990; 5:893-9.
11. Bartek J, Bartkova J, Vojtesek B, Staskova Z, Rejthar A, Kovarik I, et al. Patterns of expression of the p53 tumor suppressor in human breast tissues and tumors in situ and in vitro. Int J Cancer 1990;46:839-44.
12. Banks L, Matlashewski G, Crawford L. Isolation of human-p53-specific monoclonal antibodies and their use in the studies of human p53 expression Eur J Biochem 1986;159:529-34.
13. Cattoretti G, Rilke F, Andreola S, D'Amato L, Delia D. P53 expression in breast cancer. Int J Cancer 1988;41:178-83.
14. Davidoff AM, Herndon JE 2d, Glover NS, Kerns BJ, Pence JC, Iglehart JD, et al. Relation between p53 overexpression and established prognostic factors in breast cancer. Surgery 1991;110:259-64.
15. Ostrowski JL, Sawan A, Henry L, Wright C, Henry JA, Hennessy C, et al. p53 expression in human breast cancer related to survival and prognostic factors: an immunohistochemical study. J Pathol 1991;164:75-81.
16. Iwaya K, Tsuda H, Hiraide H, Tamaki K, Tamakuma S, Fukutomi T, et al. Nuclear p53 immunoreaction associated with poor prognosis of breast cancer. Jpn J Cancer Res 1991;82:835-40
17. Rhargava V, Thor A, Deng G, Ljung BM, Moore DH 2d, Waldman F, et al The association of p53 immunopositivity with tumor proliferation and other prognostic indicators in breast cancer. Mod Pathol 1994,7:361-8.
18. Marchetti A, Buttitta F, Pellegrini S, Campani D, Diella F, Cecchetti D, et al. p53 mutations and histological type of invasive breast carcinoma. Cancer Res 1993;53:4665-9.
19. Finlay CA, Hinds PW, Tan TH, Eliyahu D, Oren M, Levine AJ. Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with an altered half-life. Mol Cell Biol 1988;8:531-9.
20. Elledge RM, Clark GM, Fuqua SA, Yu YY, Allred DC. p53 protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer Cancer Res 1994;54:3752-7.
21. Wynford-Thomas D. P53 in tumour pathology: can we trust immunocytochemistry? [editorial] [see comment citations in Medline] J Pathol 1992;166.329-30.
22. Bergh J, Norberg T, Sjögren S, Lindgren A, Holmberg L. Complete sequencing of the p53 gene provides prognostic information in breast cancer patients, particularly in relation to adjuvant systemic therapy and radiotherapy. Nat Med 1995;1.1029-34.
23. Liljegren G, Holmberg L, Adami HO, Westman G, Graffman S, Bergh J. Sector resection with or without postoperative radiotherapy for stage I breast cancer: five-year results of a randomized trial Uppsala-Orebro Breast Cancer Study Group [see comment citations in Medline]. J Natl Cancer Inst 1994;86:717-22.
24. Lagerkvist A, Stewart J, Lagerstrom-Fermér M, Landegren U, Manifold sequencing. efficient processing of large steps of sequencing reactions. Proc Natl Acad Sci U S A 1994;91:2245-9.
25. Busch C, Malmstrom PO, Norlen BJ, Sallstrom J Brodin T, Lundblad A, et al A grading system for the immunostaining of A, B and H blood group isoanugens in bladder carcinoma Anticancer Rev 1988,8:81-8.
26. Kikuchi-Yanoshita R, Konishi M, Ito S, Seki M, Tanaka K, Maeda Y, et al Genetic changes of both p53 alleles associated with the conversion from colorectal adenoma to early carcinoma in familial adenomatous polyposis and non-familial adenomatous polyposis patients Cancer Res 1992, 52:3965-71.
27. Kerns B, Jordan P, Moore M, Humphrey P, Berchuck A, Kohler M, et al. p53 overexpression in formalin-fixed, paraffin-embedded tissue detected by immunohistochemistry J Histochem Cytochem 1992,40 1047-51
28. Mørkve O, Laerum OD Flow cytometric measurement of p53 protein expression and DNA content in paraffin-embedded tissue from bronchial carcinomas Cytometry 1991 12 438-44
29. Sarkis AS, Dalbagni G, Cordon-Cardo C, Melamed J, Zhang ZF, Sheinfeld J, et al Association of P53 nuclear overexpression and tumor progression in carcinoma in situ of the bladder J Urol 1994, 152 388-92
30. Legros Y, Lacabanne V, d Agay MF, Larsen CJ, Pla M, Soussi T Production of human p53 specific monoclonal antibodies and their use in immunohistochemical studies of tumor cells Bull Cancer (Paris) 1993, 80:102-10.
31. Brandt-Rauf P, DeVivo Ll, Dykes D, Pineus M Conformational effects of selected cancer-related amino acid substitutions in the p53 protein J Biomol Struct Dyn 1992, 10 253-64.
32. Sturzbecher HW, Addison C, Jenkins JR, Characterization of mutant p53-hsp72/73 protein-protein complexes by transient expression in monkey COS cells. Mol Cell Biol 1988;8 3740-7
33. Ohuc M, Tonnta N, Monden T, Fujita M, Fukunaga M, Takami K, et al. A frequent alteration of p53 gene in carcinoma in adenoma of colon Cancer Res 1994;54:4798-804
34. Barnes DM, Hanby AM, Gillett CE, Mohammed S, Hodgson S, Bobrow LG, et al. Abnormal expression of wild type p53 protein in normal cells of a cancer family patient. Lancet 1992;340:259-63.
35. Warren W, Eeles RA, Ponder BA, Easton DF, Averill D, Ponder MA, et al. No evidence for germline mutations in exons 5-9 of the p53 gene in 25 breast cancer families. Oncogene 1992;7:1043-6.
36. Hall PA, McKee PH, Menage HD, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal human skin. Oncogene 1993;8:203-7.
37. Shaulsky G, Ben-Ze'ev A, Rotter V, Subcellular distribution of the p53 protein during the cell cycle of Balb/c 3T3 cells. Oncogene 1990;5:1707-11.
38. Baas IO, Mulder JW, Offerhaus GJ, Vogelstein B, Hamilton SR. An evaluation of six antibodies for immunohistochemistry of mutant p53 gene product in archival colorectal neoplasms. J Pathol 1994;172:5-12.
39. Harris C p53: at the crossroads of molecular carcinogenesis and risk assessment. Science 1993;262:1980-1.